Opendata, web and dolomites

NeuroLSD SIGNED

Neuro-metabolic, structural and functional hallmarks of Lysosomal Storage Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeuroLSD project word cloud

Explore the words cloud of the NeuroLSD project. It provides you a very rough idea of what is the project "NeuroLSD" about.

accelerated    therapies    magnetic    proton    glycocerebroside    boost    share    pseudo    ratio    brain    labeling    edge    microstructural    enlarged    perivascular    gene    gd    sensitively    alteration    intracellular    methodology    parkinson    globotriaosylceramide    cutting    damage    abnormalities    brains    blood    metabolites    spin    organ    quantify    spectroscopic    lysosomal    mri    diffusion    describe    optimal    combination    comprehensively    triggers    malfunctioning    reliably    markers    administration    atrophy    continuous    storage    substances    trials    mps    spaces    neurodegenerative    progressive    reproducible    relevance    protocol    patients    alzheimer    functional    search    mucopolysaccharidosis    utilize    disease    pathology    emerges    intrathecal    prognostic    technique    clinical    bypass    morphological    age    resolution    extents    enzyme    vienna    weighted    mr    lsd    resonance    t1    chaperones    gaucher    medical    continuing    deficits    overcome    university    severe    cognitive    leukodystrophy    critically    barrier    glycosaminoglycans    imaging    vivo    psychological    diseases    levels    fabry    central    treatments    accumulation    arterial    nervous    metabolic    t2    excessive    ranging    track   

Project "NeuroLSD" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE UNIVERSITAET WIEN 

Organization address
address: SPITALGASSE 23
city: WIEN
postcode: 1090
website: www.meduniwien.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 166˙156 €
 EC max contribution 166˙156 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2021-07-18

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) coordinator 166˙156.00

Map

 Project objective

Continuing development of novel brain treatments, which bypass blood-brain barrier, further emerges the need to establish prognostic magnetic resonance (MR) markers to track progressive brain alteration in lysosomal storage diseases (LSD). Excessive intracellular accumulation of lysosomal substances such as glycosaminoglycans in mucopolysaccharidosis (MPS), globotriaosylceramide in Fabry disease and glycocerebroside in Gaucher disease (GD) triggers multi-organ malfunctioning and significant damage to the central nervous system. While LSD are associated with various levels of cognitive deficits, and distinct extents of morphological brain abnormalities (e.g., atrophy, leukodystrophy or enlarged perivascular spaces) ranging from non-existing in GD type 1 to severe in MPS type 2, microstructural and metabolic processes have not been comprehensively described in brains of LSD patients in vivo yet. We will utilize cutting-edge accelerated proton MR spectroscopic imaging methodology that was developed at the Medical University of Vienna in combination with advanced diffusion MRI, high-resolution T1-/T2-weighted ratio, and pseudo-continuous arterial spin labeling technique. Our protocol will reliably quantify levels of all relevant brain metabolites, while sensitively describe microstructural and functional deficits to determine the relevance of MR measures in psychological deficits in LSD. Reproducible MR methods are needed to assess effects of novel treatments that overcome blood-brain barrier such as intrathecal enzyme administration, chaperones and gene therapies in clinical LSD trials. Increased understanding of brain LSD pathology will critically boost search of optimal therapies in age-related neurodegenerative diseases that share some common features with LSD such as Alzheimer’s or Parkinson’s disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUROLSD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUROLSD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CLIMACY (2020)

Practices of Climate Diplomacy and Uneven Policy Responses on Climate Change on Human Mobility

Read More  

PleasDef (2019)

Exploring Women’s Sexual Pleasure Deficit

Read More  

Cartesian Networks (2020)

Cartesian Networks in Early Modern Europe: A Quantitative and Interdisciplinary Approach

Read More